Sandy Spring Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sandy Spring Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$24.7K	Hold	350	–	–	﹤0.01%	696
2024 Q4	$23K	Hold	350	–	–	﹤0.01%	723
2024 Q3	$24.6K	Sell	350 -50	-13%	-$4.18K	﹤0.01%	721
2024 Q2	$32.9K	Sell	400 -50	-11%	-$4.16K	﹤0.01%	665
2024 Q1	$39.3K	Buy	+450	New	+$40.3K	﹤0.01%	629
2021 Q3	–	Sell	-15	Closed	-$1K	–	1138
2021 Q2	$1K	Buy	+15	New	+$1.19K	﹤0.01%	1102
2021 Q1	–	Sell	-14	Closed	-$1K	–	998
2020 Q4	$1K	Buy	+14	New	+$1.11K	﹤0.01%	918
2020 Q1	–	Sell	-139	Closed	-$12K	–	900
2019 Q4	$12K	Buy	+139	New	+$10.5K	﹤0.01%	689
2019 Q3	–	Sell	-65	Closed	-$6K	–	842
2019 Q2	$6K	Buy	+65	New	+$5.56K	﹤0.01%	757

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sandy Spring Bank's BMRN Position: Q1 2025 in Review

Sandy Spring Bank held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2025 at 350 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Sandy Spring Bank first reported a position in BMRN in Q2 2019 and has held it in 9 quarters since. The position peaked at $39.3K in Q1 2024. 585 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Sandy Spring Bank held 350 shares of BioMarin Pharmaceuticals worth $24.7K as of Q1 2025.
Sandy Spring Bank left its BioMarin Pharmaceuticals share count unchanged in Q1 2025.
BioMarin Pharmaceuticals made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #696 holding.
Sandy Spring Bank first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 9 quarters since.
Sandy Spring Bank's BioMarin Pharmaceuticals position peaked at $39.3K in Q1 2024.
585 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.